Biosimilar Insulins And Insulin Analogues Stand To Erode $6.1B...

Full story: BioResearch Online

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1B in brand sales in the U.S. and Europe by 2018, saving healthcare systems $3.8B in the process.

Leave a Comment

Comments

Type in your comments to post to the forum

Name
(appears on your post)

Comments

Type the numbers you see in the image on the right:

Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Other Recent Lantus, Insulin Glargine Discussions

Topic	Updated	Last By	Comments
Trying to Find Free Insulin(Lantus) (Apr '07)	Dec 9	lainy	68
How long does Lantus last if bottle is kept ref... (Oct '07)	Nov '09	Morgan	8
Lantus Adverse Reactions (Feb '08)	Sep '09	jmbrew	4
ADA Statement on Insulin Glargine and Cancer	Sep '09	emily	3
Lantus and weight loss??? (Jan '08)	Sep '09	Marco	12
FDA reviewing safety of Sanofi's Lantus insulin (Jul '09)	Jul '09	Benjamin	5
I am unemployed and do not have much money comi... (Mar '08)	Jun '09	smile -	7